Navigation Links
Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Date:2/23/2011

ive diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis Pharmaceuticals and the discovery, development and potential of ISIS-CRPRx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ConvaTec, a privately-held medical products ... been appointed Interim Chief Executive Officer of the company, ... Ken Berger .  "The Board of Directors of ... ConvaTec over the past three years," said Magnus ... "We are confident that the company is well positioned ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 /PRNewswire/ ... Auxilium Pharmaceuticals, Inc. today announced that the Committee for ... Medicines Agency (EMA) has adopted a positive opinion for ... treatment of adult men with Peyronie,s disease with a ... degrees at the start of therapy. The ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Insights into the Marketplace and Individual Market Growth 2
... 30 CEL-SCI Corporation,(Amex: CVM ) announced that ... Rodman & Renshaw 9th Annual Healthcare Conference being,held at ... The presentation,will be focused on its Phase III cancer ... to become a new first line standard of,care treatment ...
... Oct. 29 As a follow up to ... eliminating,Methicillin resistant Staphylococcus aureus (MRSA), the Association for,Professionals ... days next,month in Atlanta to discuss new developments ... "MRSA: The Call to Action 1 Year ...
Cached Medicine Technology:CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference 2APIC Conference to Discuss MRSA Elimination 2
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... (HealthDay News) -- A new, injectable weight-loss drug has ... The agency on Tuesday approved Saxenda (liraglutide) for ... overweight and have at least one weight-related health condition, ... high cholesterol. Patients taking the drug, made by ... exercise regularly, the FDA noted. "Obesity is a ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay ... call for giving the cholesterol-lowering drugs known as statins to ... These new standards bring the association in line with the ... recommend giving low- or high-dose statins to all people at ... agree that the decision to start a statin should be ...
(Date:12/24/2014)... The 2014 Market Research Report on ... research report on COC industry. For an overview ... its definition, classification, application, industry chain structure, industry ... also presents product specification, manufacturing process, and product ... technology and applications. Analysis also covers upstream raw ...
(Date:12/24/2014)... December 24, 2014 Dental implants benefit ... a tooth replacement. They offer the strongest and most ... over other forms of tooth replacement. They will never ... the adjacent teeth for support, and they prevent the ... been told that they are not suitable candidates for ...
Breaking Medicine News(10 mins):Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 2Health News:COC/ Cyclic Olefin Copolymer Market: Global 2015-2020 Forecasts & Research Report Now at DeepResearchReports.com 3Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2
... Elsevier Middle East announces that the Journal ... been selected for inclusion in MEDLINE, the premier bibliographic database ... articles indexed, the indexing terms and the abstract printed in ... Indexing using the US National Library of Medicine,s (NLM) advanced ...
... A new independent study by HealthGrades of patient outcomes ... had a 72% lower risk of dying when compared with ... held steady over the past years even as overall mortality ... performed at the level of 5-star rated hospitals over the ...
... release is available in French . ... anesthesia has been performed at the McGill University Health ... work from remote locations, was put to work this ... providing automated anesthesia since 2008. The two combined to ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... a benefit to mothers and their infants from taking supplemental ... new Australian study finds no such benefit. In ... women, the researchers found no benefit from DHA in reducing ...
... Reporter , TUESDAY, Oct. 19 (HealthDay News) -- Patients ... attacks, stroke and other problems after their operations, and ... studies find. In the aspirin study, researchers identified ... surgeries. Of those, 860 were taking aspirin in the ...
... 2010 Dogs may not only be man,s best friend, ... of children with special needs. According to a new Universit ... the anxiety and enhance the socialization skills of children with ... Psychoneuroendocrinology may be a relatively simple solution to ...
Cached Medicine News:Health News:New ratings of American hospitals released with quality study by HealthGrades 2Health News:New ratings of American hospitals released with quality study by HealthGrades 3Health News:McSleepy meets DaVinci 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 2Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 3Health News:Fish Oil Pills Don't Affect Postpartum Depression: Study 4Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 2Health News:Aspirin, Statins May Reduce Problems After Heart Surgery 3Health News:Children's best friend 2
Pneumatic oscillating saw, 35k cpm, available with various hose connector styles....
... hand throttle. Accepts all 1000 and 2000 ... hose 9000-000, or existing hose with Microaire ... or existing hose with Linvatec/Hall connector (1000-200). ... hose with 3M connector (1000-300). , 10ft ...
Pneumatic extended oscillating saw, 35k cpm, available with various hose connector styles....
Pneumatic pencil-grip wire driver, 3000 rpm, available with various hose connector styles....
Medicine Products: